Melanoma Clinician Resources

For decades, doctors and researchers have conducted clinical trials to further progress in the clinical implementation of tumor immunotherapy. Former President Jimmy Carter’s success with immunotherapy for advanced melanoma and Vice President Joe Biden’s Cancer Moonshot Initiative have brought this new treatment type, as well as cancer treatments in general, into the spotlight for the general public. As a result, health care professionals may experience a spike in inquiries about this new treatment.

Several immunotherapy agents are now available for melanoma. Although surgery often remains the first line of treatment, especially for early-stage melanomas, the U.S. Food and Drug Administration (FDA) is rapidly approving new immunotherapy medications for advanced melanoma.

Learn more about melanoma and how immunotherapy is changing the treatment landscape in the following pages:

Melanoma_Professional_Resource_Guide_cover.jpg

This content courtesy of Immunotherapy for the Treatment of Melanoma for Health Care Professionals.

Click to download the full PDF.

Discussions

  • Dear All, I'll be attending SITC 2019 on November 7-8 and would like to network with anyone interested in or studying these topics. I'm new to the field of IO therapy and would appreciate ...

    1 person recommends this.
  • Princeton Center for Theoretical Science presents the 2019 Distinguished Visiting Lecturer Aleksandra Walczak Laboratoire de Physique Théorique Ecole Normale Supérieure Public ...

  • 2019 Annual Cancer Treatment-Related Adverse Events Symposium Friday-Saturday, October 25-26, 2019 Memorial Sloan Kettering Cancer Center  Register online: http://www.mskcc.org/AdverseEvents ...

  • Dear colleagues, I would like to personally invite you to join Kim Margolin, MD, Ahmad Tahini, MD, PhD, and myself for SITC Webinar: I-O Highlights from ASCO 2019 , a free SITC webinar ...

Resources

Nov 20, 2019 9:49 AM
Inside this Issue: Letter from the Editor  JITC Editor Picks  Other Recent JITC ARTICLES Letter from the Editor Dear JITC Readers, You are receiving this email in the weeks after SITC’s 2019 Annual Meeting and Pre-Conference Programs. This year’s meeting was a smashing success, truly highlighting ...
Nov 14, 2019 2:54 PM
In a recent issue of the Journal for ImmunoTherapy of Cancer, Badran et al. reported that co-administering Infliximab together with ICB to five cancer patients prevents colitis recurrence, with four of them exhibiting overall disease stability. The basis for this treatment strategy stemmed from the authors' ...
Nov 14, 2019 11:40 AM
Uveal melanoma (UM) is highly refractory to treatment with dismal prognosis in advanced stages. The value of the combined checkpoint blockade with CTLA-4 and PD-1 inhibition in metastatic UM is currently unclear. The authors conclude that the tolerability of the combined checkpoint blockade in UM may ...
Nov 14, 2019 11:22 AM
Adoptive transfer of autologous T-lymphocytes transduced with a high affinity NY-ESO-1-reactive T-cell receptor (NY-ESO-1 c259  T-cells) has emerged as a promising therapeutic strategy for patients with refractory synovial sarcoma. Secondary autoimmune T-cell mediated toxicities can occur long after ...